Abstract: Objective To investigate the feasibility of the gene therapy of on angiogenesis after myocardial infarction in rats. Methods Thirty-six male SD rats, after the ligation of left anterior descending coronary artery, were divided into 2 groups at random, experimental group and control group. Expressions of VEGF were measured by RT-PCR and Immunohistochemistry (IHC). Angiogenesis and capillary density were evaluated by HE stain, and qualitative and quantitative analysis were carried out. The adverse effects were tested after treating pVEGF165-PLGA nanoparticle. Results Compared with control groups, ischemic myocardial cells persistently and stably expressed VEGF in experimental group; Vascular endothelial cells proliferated actively, and the effect of angiogenesis was significant; After treating 48 hours, nanoparticles were observed in myocardial cells. Conclusion Treating with pVEGF165-PLGA nanoparticle, it can stimulate effective host-derived angiogenesis, which results in the prevention of impaired cardiac muscle after myocardial infarction. It may be an effect way to transit gene to treat MI.

Key words: myocardial infarction, nanoparticle, angiogenesis, transgenic technology